Cargando…

Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes

The effects of twice-daily GLP-1 analogue injections added on continuous subcutaneous insulin infusion (CSII) in patients with poorly controlled type 2 diabetes (T2DM) were unknown. After optimization of blood glucose in the first 3 days by CSII during hospitalization, patients with poorly controlle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chia-Hung, Hsieh, Sheng-Hwu, Sun, Jui-Hung, Tsai, Jir-Shiong, Huang, Yu-Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660278/ https://www.ncbi.nlm.nih.gov/pubmed/26607841 http://dx.doi.org/10.1038/srep16968

Ejemplares similares

Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes
por: Lin, Chia-Hung, et al.
Publicado: (2015)

Impact of Carbohydrate on Glucose Variability in Patients with Type 1 Diabetes Assessed Through Professional Continuous Glucose Monitoring: A Retrospective Study
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen
por: Lin, Yi-Hsuan, et al.
Publicado: (2022)

Sensor-augmented CSII therapy with predictive low-glucose suspend following total pancreatectomy
por: Scott, E S, et al.
Publicado: (2017)

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes
por: Lyu, Fu-ping, et al.
Publicado: (2020)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling
por: Kalra, Sanjay, et al.
Publicado: (2012)

CSII treatment as an option in high-risk pregnant patients with type 1 diabetes
por: Breder, Íkaro Soares Santos, et al.
Publicado: (2015)

Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study
por: Yao, Ming-yan, et al.
Publicado: (2019)

Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model
por: Parthsarathy, Vadivel, et al.
Publicado: (2013)

Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia
por: Buturovic, Belma Ascic, et al.
Publicado: (2014)

Professional Continuous Glucose Monitoring for the Identification of Type 1 Diabetes Mellitus Among Subjects With Insulin Therapy
por: Chen, Yin-Chun, et al.
Publicado: (2015)

Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control
por: Rhinehart, Andrew S.
Publicado: (2015)

A Potent α/β-Peptide Analogue of GLP-1 with Prolonged Action in Vivo
por: Johnson, Lisa M., et al.
Publicado: (2014)

The effects of GLP-1 analogues on pre-diabetes of the children
por: Zhou, Qing-Xia, et al.
Publicado: (2017)

Ankle-Brachial Index Is Independently Associated With Cardiovascular Outcomes and Foot Ulcers in Asian Patients With Type 2 Diabetes Mellitus
por: Yang, Ming-Chi, et al.
Publicado: (2021)

Corrigendum: Ankle-Brachial Index Is Independently Associated With Cardiovascular Outcomes and Foot Ulcers in Asian Patients With Type 2 Diabetes Mellitus
por: Yang, Ming-Chi, et al.
Publicado: (2022)

Long-Term Effects of Initiating Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring (CGM) in People with Type 1 Diabetes and Unsatisfactory Diabetes Control
por: Senn, Jon-Duri, et al.
Publicado: (2019)

Adaptability of structured forms for CSII initiation in patients with type 2 diabetes the Getting2Goal(SM) concept
por: Cohen, O., et al.
Publicado: (2016)

Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy
por: Li, Feng-fei, et al.
Publicado: (2018)

A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
por: King, Allen B., et al.
Publicado: (2016)

Postnatal growth of infants with neonatal diabetes: Insulin pump (CSII) versus Multiple Daily Injection (MDI) therapy
por: Alyafie, Fawzia, et al.
Publicado: (2019)

Development and validation of an instrument (CSII – Brazil) to assess users’ conceptual and procedural knowledge of continuous subcutaneous infusion systems
por: Amaral, Camilla Magalhães de Oliveira, et al.
Publicado: (2020)

HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment
por: Scott, Emma S, et al.
Publicado: (2019)

Evaluation of Disease Complications Among Adults With Type 1 Diabetes and a Family History of Type 2 Diabetes in Taiwan
por: Lin, Chia-Hung, et al.
Publicado: (2021)

RT‐CGM in conjunction with CSII vs MDI in optimizing glycaemic control in T1DM: Systemic review and meta‐analysis
por: William, Jimmy, et al.
Publicado: (2022)

Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials
por: Li, Hui, et al.
Publicado: (2022)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
por: Fremaux, Juliette, et al.
Publicado: (2019)

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2020)

GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling
por: Chang, Ching-Chi, et al.
Publicado: (2018)

The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD
por: Li, Cheng, et al.
Publicado: (2020)

Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes
por: Alatrach, Mariam, et al.
Publicado: (2018)

Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes - a pilot study: CSII application for children – economic evaluation
por: Petkova, Elina, et al.
Publicado: (2013)

Experiences and decision making during paediatric transitions to continuous sub-cutaneous insulin infusion (CSII): A mixed method study
por: Altmann, Erika, et al.
Publicado: (2018)

Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2021)

Analogue to Digital and Digital to Analogue (AD/DA) Conversion Techniques: An Overview
por: John Pett (SL-PO)
Publicado: (2002)

SUN-148 Are Glp Analogues Superior For Diabetes And Weight Control In Patients On Antidepressant Medications?
por: Azim, Salman, et al.
Publicado: (2019)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
por: Saraiva, José Francisco Kerr, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o6tb52gl91rgc0e5g747ctgp49